| Oct 30 |
Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.
|
| Oct 30 |
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
|
| Oct 30 |
Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
|
| Oct 30 |
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
|
| Oct 30 |
Biogen, Sage admit a defeat in major depression
|
| Oct 30 |
Biogen raises annual earnings guidance, tops Q3 estimates; shares up
|
| Oct 30 |
Biogen raises Forecast as Alzheimer’s drug Leqembi shows signs of growth
|
| Oct 30 |
Biogen Non-GAAP EPS of $4.08 beats by $0.29, revenue of $2.46B beats by $30M
|
| Oct 30 |
Biogen raises annual profit forecast as new treatments boost earnings
|
| Oct 30 |
Biogen optimistic as new products gain traction
|
